Executive Summary Rapid expansion through acquisition or market entry is a significant risk factor for pharmacovigilance (PV) systems in small and medium-sized enterprises. Structures built for steady-state operations often fracture under sudden pressure, leaving leadership in a reactive crisis … Read More
DIA Europe Annual Meeting 2026
By Stefan Brüning, Co-Founder Consulting Practice Lead at VIGINEXT. Stefan Brüning is Co-Founder and Consulting Practice Lead at VIGINEXT. With over a decade of experience across the CRO, pharmaceutical, and biotech sectors, Stefan specializes in the strategic development of Pharmacovigilance (PV) Ecosystems … Read More
Why Biotech and Pharma Companies Need Independent Safety Systems for Clinical Trials
By Stefan Brüning, Managing Director at Viginext Advisors GmbH Stefan Brüning is a pharmacovigilance expert with over 13 years of experience in the pharmaceutical industry. As the founder and Managing Director of Viginext Advisors GmbH, he specializes in helping biotech … Read More